Which Mammography Recommendation Results in the Greatest Breast Cancer Mortality Reduction?
BACKGROUND AND PURPOSE:
Evidence demonstrates a reduction in breast cancer deaths due to routine screening mammography
Data limitations remain, even with RCTs, due to older mammography machines, different protocols and possible noncompliance
Computer models can overcome some of these issues
NCI has funded the Cancer Intervention and Surveillance Modeling Network (CISNET) to develop these models
Arleo et al. (Cancer, 2017) sought to determine which screening approach prevented the most deaths
Benefits and risks of each screening technique were used to evaluate three common screening guideline approaches
Annual screening at ages 40 to 84 y/o (Option 1)
Annual screening at ages 45 to 54 y/o, and biennially 55 to 79 y/o (Option 2)
Annual screening at ages 50-74 y/o (Option 3)
CISNET had six groups at different institutions develop independent computer models
Input parameters estimates of breast cancer incidence, survival trends with and without screening or adjuvant therapy, mammography performance data from the Breast Cancer Surveillance Consortium (BCSC), and breast cancer-specific mortality data from the SEER Program
Risk of overdiagnosis was not included
Mean mortality reduction was greatest with Option 1 (39.6%) compared to Option 2 (30.8%) and Option 3 (23.2%)
Option 1 would avert the greatest number of breast cancer deaths (29,369) compared to Option 2 (22,829) and Option 3 (15,599; cohort of women born in 1970)
Option 1 would also lead to the most mammograms (90.2 million), benign recalls (6.8 million), and benign biopsies (481,269) compared to Option 2 (49.0 million, 4.1 million, and 286,288, respectively) or Option 3 (27.3 million, 2.3 million, and 162,885, respectively)
Mean mortality reduction is greatest in with annual screening beginning at age 40 (39.6%) compared to hybrid annual/biennial (30.8%) or annual screening beginning at age 50 (26.6% using 1970 birth cohort).
In the accompanying editorial, the author summarizes the evidence used by guideline committees
Regular screening is effective in reducing breast cancer mortality for women aged 40 to 74 years
The likelihood of screening benefit increases with age (mammography is a better test for women in their 50s than it is for women in their 40s)
There is risk of harm associated with screening
One must balance the benefits and risks when deciding about screening
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan